ClinicalTrials.gg
CompletedNCT00644631Updated Feb 1, 2021

A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate

A Phase 4 interventional study of sildenafil and placebo in Erectile Dysfunction, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 31 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.

Planned enrollment
10th of 50
300 · median 108
Started
2003
with 4 others
Phase 4
30 of 50
none open now
Registered
25th of 50
by date
Lead sponsor
23 of 50
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 10th largest by planned enrollment, is one of 5 that started in 2003, is one of 30 in phase 4, and was the 25th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing sildenafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

To compare the effects of sildenafil versus placebo on the female partner's sexual satisfaction as assessed by Question 3 of Female Partner of Erectile Dysfunction (ED) Subject Questionnaire (FePEDS-Q): "Over the past 4 weeks, when you had sexual intercourse, how often was it satisfactory for you?" For ED subjects, determine difference in the Erectile Function domain of International Index of Erectile Function (IIEF) between sildenafil citrate and placebo at end of the treatment phase and determine the overall relationship between improved erectile function and increased ED subject and female partner satisfaction.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The male patient must have had a documented clinical diagnosis of erectile dysfunction (ED) confirmed by a Sexual Health Inventory-Male (SHI-M) score of less than or equal to 21
  • a stable female partner at least 21 years of age for at least 6 months prior to screening
  • the couple must have been married or living together at the time of screening.
  • The female partner must have answered "no intercourse," "sometimes," "a few times" or "almost never" on Question 3 of the Female Partner of ED Subject Questionnaire (FePEDS-Q)

Exclusion criteria

Exclusion Criteria:

  • The male patient must not have had resting sitting and/or standing hypotension (BP \< 90/50mmHg) or hypertension (BP > 170/110mmHg), or significant cardiovascular disease in the last 3 months, including cardiac failure, myocardial infarction, unstable angina, stroke, (TIA), symptomatic or cardiac arrhythmias.
  • Female partners must not have had significant dyspareunia or lifelong significant sexual dysfunction based on female partner's medical and sexual history at screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Arm 1

    Drug: sildenafil

  • Placebo comparator
    Arm 2

    Drug: placebo

Interventions

  • sildenafil 50 mg (initial dose) tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks; depending upon safety, efficacy and tolerability, the dose could be increased to 100 mg or reduced to 25 mg, if necessary.

  • Drugplacebo

    placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks

06

What researchers measure

Primary outcomes

  1. Question 3 of the Female Partner ED Subject Questionnaire (FePEDS-Q) in female partners.

    Time frame: Week 12

Secondary outcomes

  1. International Index of Erectile Function (IIEF) Erectile Function, Desire, Orgasm, Intercourse Satisfaction, and Overall Satisfaction Domains in ED patients

    Time frame: Week 8 and Week 12

  2. Self-Esteem and Relationship Questionnaire (SEAR) in ED patients

    Time frame: Week 12

  3. ED Subject Event Log in ED patients

    Time frame: Week 12

  4. Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) index of treatment satisfaction in ED patients

    Time frame: Week 12

  5. Dyadic Adjustment Scale (DAS) in ED patients

    Time frame: Week 8 and Week 12

  6. American Urological Association (AUA) Symptom Index in ED patients

    Time frame: Week 12

  7. Global Efficacy Assessment Questions (GEQ) in ED patients

    Time frame: Week 12

  8. Questions 1 and 2 of Female Partner of ED Subject Questionnaire (FePEDS-Q) in female partners

    Time frame: Week 8 and Week 12

  9. Sexual Function Questionnaire (SFQ) Desire, Arousal, Enjoyment and Orgasm Domains in female partners

    Time frame: Week 12

  10. Female Sexual Function Inventory (FSFI) Desire, Satisfaction and Arousal Domains in female partners

    Time frame: Week 12

  11. Partner EDITS in female partners

    Time frame: Week 12

  12. Female Partner Treatment Continuation Question in female partners

    Time frame: Week 12

  13. Dyadic Adjustment Scale (DAS) in female partners

    Time frame: Week 8 and Week 12

  14. Beck Depression Inventory (BDI-II) in female partners

    Time frame: Week 12

  15. Female Partner Event Log in female partners

    Time frame: Week 12

  16. AUA Symptom Index in female partners

    Time frame: Week 12

07

Study locations

31 sites
  • Pfizer Investigational Site
    Huntsville, Alabama 35801, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas, United States
  • Pfizer Investigational Site
    Beverly Hills, California 90212, United States
  • Pfizer Investigational Site
    Laguna Woods, California 92653, United States
  • Pfizer Investigational Site
    Los Angeles, California 90033, United States
  • Pfizer Investigational Site
    Los Angeles, California 90073, United States
  • Pfizer Investigational Site
    Palo Alto, California 94305, United States
  • Pfizer Investigational Site
    Torrance, California 90505, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80012, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06708, United States
  • Pfizer Investigational Site
    Ocala, Florida 34474, United States
  • Pfizer Investigational Site
    Peoria, Illinois 61614, United States
  • Pfizer Investigational Site
    Jeffersonville, Indiana 47130, United States
  • Pfizer Investigational Site
    Des Moines, Iowa 50314, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66215, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21204, United States
  • Pfizer Investigational Site
    Peabody, Massachusetts 01960, United States
  • Pfizer Investigational Site
    Saint Louis, Missouri 63117, United States
  • Pfizer Investigational Site
    Garden City, New York 11530, United States
  • Pfizer Investigational Site
    New York, New York 10016, United States
  • Pfizer Investigational Site
    New York, New York 10032, United States
  • Pfizer Investigational Site
    Poughkeepsie, New York 12601, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27705, United States
  • Pfizer Investigational Site
    Beachwood, Ohio 44122-5402, United States
  • Pfizer Investigational Site
    Newtown, Pennsylvania 18940, United States
  • Pfizer Investigational Site
    Knoxville, Tennessee 37920, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Lacey, Washington 98516, United States
  • Pfizer Investigational Site
    Seattle, Washington 98105, United States
  • Pfizer Investigational Site
    Spokane, Washington 99207, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2008
First posted
Mar 27, 2008
Start
Jun 2003
CompletionActual
Apr 2004
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00644631
Responsible party
Sponsor
First posted
Mar 27, 2008
Start date
Jun 2003
Completion
Apr 2004
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion